Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ILV-095 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ILV-095 | ACTIVE_COMPARATOR | 6 SC single dose injections |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ILV-095 | BIOLOGICAL | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Men aged 20 to 45 years inclusive at screening. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after study drug administration. * Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body...
ILV-095 is an investigational monoclonal antibody developed by Pfizer, Inc. (ticker PFE). It is in Phase 1 clinical development, and its specific therapeutic indication has not been disclosed. The program has completed two Phase 1 trials in healthy volunteers, one in the United States and one in Japan.
ILV-095 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored both Phase 1 clinical trials of the monoclonal antibody, one conducted in the United States and one in Japan, each enrolling 48 healthy subjects.
ILV-095 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The studies were randomized, double-blind, and placebo-controlled, with a combined enrollment of 96 healthy subjects across the United States and Japan.
ILV-095 has been studied in two completed Phase 1 trials. NCT00822835 evaluated single doses in healthy subjects in the United States, and NCT00822484 evaluated single doses in healthy Japanese male subjects in Japan. Each trial enrolled 48 participants, and both were randomized, double-blind, and placebo-controlled.
ILV-095 is not approved. It is an investigational monoclonal antibody still in Phase 1 clinical development, with two completed Phase 1 trials in healthy volunteers. Pfizer, Inc. (ticker PFE) is the developer.